Covid Segment To Be As Big A Part Of Revenue As Non-Covid Segment For Laboratories: A Velumani

Covid segment to be as big a part of revenue as non-Covid segment for laboratories: A Velumani

The Economic Times

Dr. Velumani talks about How big is the Covid business compared to Non-Covid?

BlueCircle: Green Jobs & Learning Network

Without herd immunity there is no relief from Covid-19: A Velumani, Thyrocare Tech

The Economic Times

Dr Velumani Talks At Festival of HealthTech 2023 #ytshorts #businessworld #health #healthcare

Thyrocare's A Velumani On Covid-19 Testing In India

Covid-19: Testing Not A Problem, Diagnostic Labs Face Logistical Challenges| IndiaSpend l A Velumani

Early data proves Indians are better immunised against COVID-19 | Dr Velumani, MD - Thyrocare

Demand for Cheaper COVID-19 Tests | Dr A Velumani of Thyrocare Technologies To ET NOW

TN struggles with shortage of only monoclonal antibody that works for COVID's omicron variant

WBIR Channel 10

RT-PCR is the most reliable test in the covid diagnosis: Dr A. Velumani, CEO, Thyrocare Technologies

"Laboratories sending too many positive COVID results get calls from above"| Thyrocare's Velumani

Healthcare's Evolving Equation Post Covid | National Heart Institute

National Heart Institute

Daily COVID Cases Declining - Is India Out Of Woods Yet? | Thyrocare's Dr A Velumani To ET Now

Dr A Velumani discusses the second wave of COVID pandemic | ET Now

COVID-19 Booster and Vaccines: Doctor Answers Your Questions

UC San Diego Health

COVID-19 cases rise in India, Secon wave fears intensify? | Dr A Velumani to ET NOW

Insight | Thyrocare's Strategy To Improve Margins | BQ Prime

Day 1 - Grand Challenges in COVID-19 Healthcare

COVID-19 laboratory innovations: Sequencing and diagnostics

Mayo Clinic Laboratories

India in the midst of a second COVID-19 wave? | Thyrocare MD Dr A Velumani to ET NOW